Zions Bancorporation’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $321K | Buy |
3,590
+310
| +9% | +$27.3K | 0.02% | 289 |
|
|
2024
Q3 | $275K | Sell |
3,280
-713
| -18% | -$56.2K | 0.02% | 302 |
|
|
2024
Q2 | $308K | Sell |
3,993
-849
| -18% | -$62.1K | 0.02% | 281 |
|
|
2024
Q1 | $332K | Sell |
4,842
-125
| -3% | -$8.04K | 0.02% | 287 |
|
|
2023
Q4 | $287K | Sell |
4,967
-633
| -11% | -$33.8K | 0.02% | 289 |
|
|
2023
Q3 | $296K | Buy |
5,600
+847
| +18% | +$44.4K | 0.03% | 279 |
|
|
2023
Q2 | $257K | Buy |
4,753
+3,209
| +208% | +$168K | 0.02% | 290 |
|
|
2023
Q1 | $77.2K | Sell |
1,544
-249
| -14% | -$11.7K | 0.01% | 381 |
|
|
2022
Q4 | $83K | Buy |
1,793
+231
| +15% | +$10K | 0.01% | 379 |
|
|
2022
Q3 | $60K | Buy |
1,562
+74
| +5% | +$2.97K | 0.01% | 406 |
|
|
2022
Q2 | $55K | Sell |
1,488
-1,227
| -45% | -$49.9K | 0.01% | 453 |
|
|
2022
Q1 | $120K | Buy |
2,715
+25
| +0.9% | +$1.08K | 0.01% | 393 |
|
|
2021
Q4 | $114K | Sell |
2,690
-215
| -7% | -$9.04K | 0.01% | 363 |
|
|
2021
Q3 | $126K | Buy |
2,905
+955
| +49% | +$42.3K | 0.01% | 338 |
|
|
2021
Q2 | $83K | Sell |
1,950
-36
| -2% | -$1.51K | 0.01% | 369 |
|
|
2021
Q1 | $77K | Buy |
1,986
+1,018
| +105% | +$38.5K | 0.01% | 366 |
|
|
2020
Q4 | $35K | Sell |
968
-6,696
| -87% | -$241K | ﹤0.01% | 451 |
|
|
2020
Q3 | $293K | Buy |
7,664
+1,685
| +28% | +$64.9K | 0.04% | 165 |
|
|
2020
Q2 | $210K | Buy |
5,979
+4,951
| +482% | +$178K | 0.03% | 210 |
|
|
2020
Q1 | $34K | Sell |
1,028
-6,111
| -86% | -$239K | 0.01% | 367 |
|
|
2019
Q4 | $323K | Buy |
7,139
+5,272
| +282% | +$221K | 0.05% | 140 |
|
|
2019
Q3 | $76K | Hold |
1,867
| – | – | 0.01% | 359 |
|
|
2019
Q2 | $80K | Sell |
1,867
-786
| -30% | -$30.2K | 0.01% | 327 |
|
|
2019
Q1 | $102K | Buy |
+2,653
| New | +$101K | 0.02% | 305 |
|
|
2018
Q4 | – | Sell |
-4,197
| Closed | -$162K | – | 535 |
|
|
2018
Q3 | $162K | Buy |
+4,197
| New | +$147K | 0.04% | 193 |
|
|
2018
Q2 | – | Sell |
-4,662
| Closed | -$127K | – | 472 |
|
|
2018
Q1 | $127K | Buy |
4,662
+136
| +3% | +$3.7K | 0.03% | 173 |
|
|
2017
Q4 | $112K | Sell |
4,526
-14,932
| -77% | -$412K | 0.02% | 219 |
|
|
2017
Q3 | $568K | Buy |
19,458
+19,286
| +11,213% | +$533K | 0.08% | 138 |
|
|
2017
Q2 | $5K | Sell |
172
-159
| -48% | -$4.22K | ﹤0.01% | 431 |
|
|
2017
Q1 | $9K | Sell |
331
-250
| -43% | -$6.08K | ﹤0.01% | 380 |
|
|
2016
Q4 | $12K | Buy |
581
+235
| +68% | +$5.13K | ﹤0.01% | 464 |
|
|
2016
Q3 | $7K | Hold |
346
| – | – | ﹤0.01% | 543 |
|
|
2016
Q2 | $8K | Hold |
346
| – | – | ﹤0.01% | 473 |
|
|
2016
Q1 | $8K | Sell |
346
-1,000
| -74% | -$17.6K | ﹤0.01% | 555 |
|
|
2015
Q4 | $22K | Buy |
1,346
+1,000
| +289% | +$17.9K | ﹤0.01% | 339 |
|
|
2015
Q3 | $6K | Buy |
+346
| New | +$5.91K | ﹤0.01% | 569 |
|
|
2015
Q2 | – | Sell |
-1,283
| Closed | -$23K | – | 324 |
|
|
2015
Q1 | $23K | Buy |
+1,283
| New | +$20.3K | ﹤0.01% | 339 |
|
Other funds holding BSX
Zions Bancorporation's BSX Position: Q4 2024 in Review
Zions Bancorporation increased its Boston Scientific (BSX) stake by 9.5% in Q4 2024, buying an estimated $27.3K and bringing the position to 3,590 shares worth $321K. The position accounts for 0.02% of the portfolio, ranked #289.
Zions Bancorporation first reported a position in BSX in Q1 2015 and has held it in 37 quarters since. The position peaked at $568K in Q3 2017. 1,513 funds tracked by Wall St. Rank hold BSX as of Q4 2024.
- Zions Bancorporation held 3,590 shares of Boston Scientific worth $321K as of Q4 2024.
- Zions Bancorporation bought 310 Boston Scientific shares in Q4 2024, an estimated $27.3K.
- Boston Scientific made up 0.02% of Zions Bancorporation's portfolio in Q4 2024, its #289 holding.
- Zions Bancorporation first reported a position in Boston Scientific in Q1 2015 and has held it in 37 quarters since.
- Zions Bancorporation's Boston Scientific position peaked at $568K in Q3 2017.
- 1,513 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2024.
Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.